RARE

AI Memo

Ultragenyx Pharmaceutical

As of 2026-01-06/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-01-06 • Model: RankAlpha Sentiment AI

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

—

Key catalyst

Phase readout for late-stage program (window end) • 2026-09-30

Expected move: -4%

Biggest risk

Clinical failure, regulatory setbacks, or capital constraints force dilution and timeline extensions, compressing valuation toward downside levels.

Invalidation

Break below $12 or thesis failure.

What would change my mind?

Successful readouts and regulatory progress validate pricing for niche indications, enabling meaningful re-rating and significant upside from current levels.

Research note

Recommendation

—

Confidence

medium

As of

2026-01-06

Base target

$23

p=60%

Bull target

$46

p=20%

Bear target

$12

p=20%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Next quarterly financial report (10-Q) / corporate update
Regulatory milestone / early commercial uptake
Successful readouts and regulatory progress validate pricing for niche indications, enabling meaningful re-rating and significant upside from current levels.

BearKey bullets

Clinical trial failure or negative topline
Funding shortfall and equity dilution
Regulatory delay or adverse decision

WatchKey bullets

Phase readout for late-stage program (window end)

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $23 (p=60%)

Bull/Bear spread: +93% / -52%

Vs latest close: Bull +93% · Base -4% · Bear -52%

Scenario probabilities

Bull Target: $46 (p=20%)Base Target: $23 (p=60%)Bear Target: $12 (p=20%)

Commentary

Investors are cautious and focused on upcoming readouts and cash-runway commentary; buying interest is contingent on binary clinical outcomes [#NEWS-2026-01-05]. Corporate messaging stresses program prioritization and cost discipline, which tempers but does not eliminate upside expectations pending milestones [#PR-2025-11-01].

As of 2026-01-06 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Successful readouts and regulatory progress validate pricing for niche indications, enabling meaningful re-rating and significant upside from current levels.

Bear Case

Clinical failure, regulatory setbacks, or capital constraints force dilution and timeline extensions, compressing valuation toward downside levels.

Drivers

Scannable catalysts and supporting factors

Next quarterly financial report (10-Q) / corporate update
Regulatory milestone / early commercial uptake

Scenarios

Bull Target (Scenario probability)

$46 / p=20% prob

Base Target (Scenario probability)

$23 / p=60% prob

Bear Target (Scenario probability)

$12 / p=20% prob

Price $24 as of 2026-05-29

Nearest Scenario: Base (∆ 4%)

Targets vs latest close: Bull +93% · Base -4% · Bear -52%

Sentiment & Exposure

Sentiment unavailable: insufficient coverage

Events

Other notable items detected

EVENT2026-09-30
Phase readout for late-stage program (window end)
Pivotal readout for a lead program; date uses a window-end assumption due to no public schedule [#PR-WindowAssumption].
Prob 30.00% • Move 50.00% • Priced-in 20.00%

Short-term Catalysts

Next few weeks

Next quarterly financial report (10-Q) / corporate update
2026-04-06
Quarterly results updating cash runway and program timelines; date set to the next filing window [#10Q-Est].
Prob 95% • Move 6% • Priced-in 40%

Long-term Catalysts

Months to a year

Regulatory milestone / early commercial uptake
2027-01-06
Regulatory filing/decision or early commercial metrics that would materially alter revenue trajectory; conservative one-year horizon [#CorpPlan-Est].
Prob 25% • Move 80% • Priced-in 10%

Risks

Clinical trial failure or negative topline
Funding shortfall and equity dilution
Regulatory delay or adverse decision
Slower-than-expected reimbursement/commercial uptake

Peers

Symbol	Summary
BMRN	BioMarin: established rare-disease commercial and gene-therapy experience; useful comparator.
FOLD	Amicus Therapeutics: rare-disease focus with comparable commercialization and reimbursement dynamics.
RGNX	Regenxbio: gene-therapy platform peer with similar development cadence and regulatory variability.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment AI
Analysis date: 2026-01-06

AI Stock Memo: RARE - Ultragenyx Pharmaceutical - RankAlpha